MO-BENSON-HILL
18.1.2023 13:01:35 CET | Business Wire | Press release
Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), a food tech company unlocking the natural genetic diversity of plants, announced today that it became one of the first U.S.-based ingredient providers to achieve the international ProTerra Certification, a rigorous global standard that sets the bar for sustainable agricultural practices and labor practices as well as segregated non-GMO programs and more. Benson Hill also joins the respected ProTerra Network, a group of companies dedicated to sustainable practices and continuous improvement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005254/en/
Benson Hill Achieves ProTerra Sustainability Certification for its Proprietary Non-GMO Soy Portfolio. The company is one of the first U.S.-based ingredient providers to verify its sustainable practices under rigorous global standard. (Photo: Business Wire)
The ProTerra Certification program promotes social and environmental sustainability through food and feed supply chains, to support efforts to continuously improve day-to-day business operations and to help organizations to engage and implement the concept of sustainable development.
Throughout an extensive certification process, Benson Hill completed audits of its Creston, Iowa, and Seymour, Ind., plants as well as two shipping ports that store and transport its non-GMO soymeal. Benson Hill also partnered with its growers to conduct several on-farm visits. These in-depth audits examined data related to identity preservation along with deforestation practices, biodiversity efforts, and other Environmental, Social and Governance (ESG) metrics such as fair labor practices.
“I am delighted to welcome Benson Hill as a ProTerra Network Member. This certification demonstrates their engagement to continuously improve agricultural practices and achieve full transparency in the food supply chain,” said Emese van Maanen, Managing Director for the ProTerra Foundation. “Collaboration with farmers is essential to developing long-term relationships that create benefits from plant to plate.”
“Through our journey with ProTerra we gained important insights to solidify our position as a global ingredients company focused on responsible growth,” said Andres Martin, Executive Vice President and General Manager, International for Benson Hill. “Achieving the ProTerra certification standard is a testament to the ESG principles guiding our work to sustainably deliver our non-GMO soybean portfolio to markets within and outside the United States.”
The ProTerra standard, against which organizations are certified, is based on the Basel Criteria for Responsible Soy (created by Coop Switzerland and World Wildlife Fund). Today the standard is applicable to all sectors of the food and agricultural system worldwide and at all stages of the food chain. In addition, ProTerra certification ensures that high quality supplies of crops, food, and feed, that are independently certified as non-GMO and produced with improved sustainability, are available on the global market. Benson Hill’s proprietary soy ingredient portfolio, designed to meet specific end uses with less processing and increased traceability, is currently available in North America and in Europe.
Benson Hill built its closed-loop business model on sustainable design and systems thinking, which means its products deliver benefits across the entire value chain, from seed to plate. For example, CleanCRUSH™ ingredients derived from the company’s proprietary soybean genetics are designed as a less-processed alternative to commodity soy protein concentrate (SPC). CleanCRUSH ingredients can also reduce the need for costly energy- and water-intensive protein concentrating steps traditionally required for plant-based protein and aquaculture feed applications. In SPC comparisons, this can result in up to a 50 to 90 percent reduction in CO2e, depending on the ingredient source, and up to a 70 percent reduction in water usage.
For more information about Benson Hill’s progress in assessing impact and setting the pace of innovation in food, download its inaugural Environmental, Social and Governance (ESG) Report released in July 2022.
About Benson Hill
Benson Hill moves food forward with the CropOS® platform, a cutting-edge food innovation engine that combines data science and machine learning with biology and genetics. Benson Hill empowers innovators to unlock nature’s genetic diversity from plant to plate, with the purpose of creating nutritious, great-tasting food and ingredient options that are both widely accessible and sustainable. More information can be found at bensonhill.com or on Twitter at @bensonhillinc.
About ProTerra Foundation
The ProTerra Foundation is a not-for-profit organization located in the Netherlands that advances and promotes sustainability at all levels of the feed and food production system. Its mission is to be a global network of businesses supporting more sustainable agricultural practices in the agribusiness supply chains. The ProTerra Standard has been developed to promote social and environmental sustainability through the food and feed supply chains, to support stakeholders in their efforts to continuously improve their day-to-day business and to help organizations in engaging and implementing the concept of sustainable development. For details, please visit www.proterrafoundation.org.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may be identified by words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” or similar words. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements include, among other things, statements regarding: the anticipated benefits of the Company’s ProTerra certification, ongoing sustainability and ESG initiatives, and farmer collaborations; the Company’s plans to promote sustainable agricultural practices and enhanced food supply chain transparency; anticipated advantages of the Company’s CleanCRUSH ingredients, including expectations regarding reduced carbon emissions and water usage; industry conditions and trends; the Company’s strategy and plans for growth; the expected future performance of and demand for the Company’s products; the Company’s ability to manage, develop and sustainably deliver its products to domestic and international markets; expectations about the markets in which the Company participates; and statements regarding the Company’s competitive positioning, resources, capabilities, and expectations for future performance. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, risks associated with: the Company’s ability to realize the expected benefits of its ProTerra certification and to maintain its ProTerra certification; the Company’s ability to realize benefits associated with its ongoing sustainability and ESG initiatives and farmer collaborations; the success of the Company’s products and their ability to achieve expected results, including results related to sustainability benefits; the Company’s ability to grow and achieve growth profitably; the Company’s ability to maintain relationships with its customers, suppliers and strategic partners; changing industry conditions and consumer preferences; the Company’s ability to retain key personnel and generally execute on its business strategy; global and regional economic, agricultural, financial and commodities markets; political, social and health conditions, both domestically and internationally; the Company’s transition to becoming a public company; the effectiveness of the Company’s risk management strategies; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in our filings with the Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. We expressly disclaim any duty to update these forward-looking statements, except as otherwise required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005254/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
